{"id":"NCT01338415","sponsor":"Actelion","briefTitle":"FUTURE 3 Study Extension","officialTitle":"A Prospective, Multicenter, Open-label Extension of FUTURE 3 to Assess the Safety, Tolerability and Efficacy of the Pediatric Formulation of Bosentan Two Versus Three Times a Day in Children With Pulmonary Arterial Hypertension","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-03-08","primaryCompletion":"2014-08-13","completion":"2020-05-29","firstPosted":"2011-04-19","resultsPosted":"2017-12-11","lastUpdate":"2025-03-30"},"enrollment":58,"design":{"allocation":"NON_RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Pulmonary Arterial Hypertension"],"interventions":[{"type":"DRUG","name":"Bosentan","otherNames":["ACT-050088"]}],"arms":[{"label":"bosentan 2mg/kg b.i.d.","type":"EXPERIMENTAL"},{"label":"bosentan 2mg/kg t.i.d.","type":"EXPERIMENTAL"}],"summary":"The objectives of the FUTURE 3 Study Extension are to evaluate the long-term safety, tolerability and efficacy of the pediatric formulation of bosentan two versus three times a day in children with Pulmonary Arterial Hypertension (PAH).","primaryOutcome":{"measure":"Treatment Emergent Adverse Events (AEs) up to 7 Days After Permanent Study Drug Discontinuation","timeFrame":"Up to 62 weeks in average","effectByArm":[{"arm":"Bosentan 2mg/kg b.i.d.","deltaMin":29,"sd":null},{"arm":"Bosentan 2mg/kg t.i.d.","deltaMin":26,"sd":null}],"pValues":[]},"eligibility":{"minAge":"3 Months","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":36,"countries":["United States","Australia","Belarus","China","Czechia","France","Germany","Hungary","India","Israel","Italy","Mexico","Poland","Russia","Serbia","South Africa","Spain","Ukraine"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":15,"n":33},"commonTop":["UPPER RESPIRATORY TRACT INFECTION","PYREXIA","NASOPHARYNGITIS","VOMITING","VIRAL UPPER RESPIRATORY TRACT INFECTION"]}}